AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

The mega investment is in line with Astrazeneca’s global ambition to achieve 80 billion dollars in Total Revenue and to bring ...

Cambridge headquartered global pharma company AstraZeneca is investing C$820 million (US$570m) in Canada, creating more than ...

AstraZeneca plans C$820 million investment in Canada to advance growing global hub and clinical delivery: Mississauga, Ontario Saturday, January 25, 2025, 09:00 Hrs [IST] AstraZen ...

AstraZeneca said it has created more than 1,200 jobs and invested more than $1.3-billion CAD in Canada since 2023. The ...

AstraZeneca announced a new investment in Canada to support the company’s move into a larger, more modern facility in Greater ...

AstraZeneca will invest 820 million Canadian dollars, equivalent to $570.3 million, to facilitate a move to a larger office in the Toronto metro area. The Anglo-Swedish pharmaceutical giant said ...

U.K. pharmaceutical company says Canadian presence will contribute to its goal of bringing 20 new medicines to market by 2030 ...